scout
Opinion|Videos|September 30, 2024

Exploring Updates in TiNivo-2 From ESMO 2024

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME